Combination of [68Ga]Ga-PSMA PET/CT and [18F]FDG PET/CT in demonstrating dedifferentiation in castration-resistant prostate cancer

Basit Öğe Kaydı
dc.contributor.authorKepenek, F.
dc.contributor.authorCan, C.
dc.contributor.authorKomek, H.
dc.contributor.authorKaplan, I
dc.contributor.authorGundogan, C.
dc.contributor.authorEbinc, S.
dc.contributor.authorGuzel, Y.
dc.date.accessioned2024-04-24T16:15:27Z
dc.date.available2024-04-24T16:15:27Z
dc.date.issued2023
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim of the study. - In this study, we aimed to determine the factors affecting increased glucose metabolism, which is one of the dedifferentiation mechanisms, by using [18F]FDG and [68Ga]Ga-PSMA PET/CT in patients with castration-resistant prostate cancer (CRPC).Materials and method. - Ninety-three patients with CRPC were included in the study. Gleason score (GS), and total PSA and free PSA levels of the patients were recorded. Patient-and organ-based evaluations were performed according to the lesion uptakes as follows: score 0: PSMA (-) FDG (-), score 1: PSMA (+) FDG (-), score 2: PSMA (+) FDG (+) (FDG < PSMA), score 3: PSMA (+) FDG (+) (FDG = PSMA), score 4: PSMA (+) FDG (+) (FDG > PSMA), and score 5: PSMA (-) FDG (+). scores 1 and 2 were classified as group 1, and scores 3 to 5 were classified as group 2.Results. - The median age of our patients was 70 (51-88) years. Eighty-eight patients (94.6%) were PSMA-positive, 78 patients (83.8%) were FDG-positive, and 89 patients (95.6%) were or PSMA or FDG positive. When the two groups were compared in terms of patient-based parameters, the median age and GS were found to be significantly higher in group 2. ROC analyses revealed that age and GS were significant in predicting group 2.Conclusion. - Since glucose metabolism can increase in CRPC patients with advanced age and high GS, we recommend combining [18F]FDG PET/CT with [68Ga]Ga-PSMA PET/CT in routine clinical practice in order to identify this patient subset and refer them to additional therapies. ?@ 2023 Published by Elsevier Masson SAS.en_US
dc.identifier.doi10.1016/j.mednuc.2022.12.001
dc.identifier.endpage199en_US
dc.identifier.issn0928-1258
dc.identifier.issn1878-6820
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85150371262
dc.identifier.scopusqualityQ4
dc.identifier.startpage193en_US
dc.identifier.urihttps://doi.org/10.1016/j.mednuc.2022.12.001
dc.identifier.urihttps://hdl.handle.net/11468/15809
dc.identifier.volume47en_US
dc.identifier.wosWOS:001052831300001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherElsevier France-Editions Scientifiques Medicales Elsevieren_US
dc.relation.ispartofMedecine Nucleaire-Imagerie Fonctionnelle Et Metabolique
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPsmaen_US
dc.subjectPeten_US
dc.subjectCten_US
dc.subjectProstate Canceren_US
dc.subjectCastration Resistanceen_US
dc.subjectGlucose Metabolismen_US
dc.subject[18f]Fdgen_US
dc.titleCombination of [68Ga]Ga-PSMA PET/CT and [18F]FDG PET/CT in demonstrating dedifferentiation in castration-resistant prostate canceren_US
dc.titleCombination of [68Ga]Ga-PSMA PET/CT and [18F]FDG PET/CT in demonstrating dedifferentiation in castration-resistant prostate cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu